Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05384782
Other study ID # Version 10
Secondary ID 260729
Status Completed
Phase
First received
Last updated
Start date December 1, 2019
Est. completion date March 31, 2022

Study information

Verified date May 2022
Source Cornwall Partnership NHS Foundation Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The primary aim is to validate a set of computational biomarkers as potential decision support in epilepsy on a large cohort of study participants that were diagnosed with epilepsy and controls that ended up with another diagnosis (such as syncope or non-epileptic seizures). The goal is to examine if the methodology works robustly on this large cohort, and can theoretically contribute to the reduction of misdiagnosis rates. The secondary aim is to examine whether the computational biomarkers could contribute to reducing the waiting time and the number of clinical appointments needed before a final diagnosis is made.


Description:

Mathematical models provide a powerful and useful tool with which to identify and understand biological mechanisms that may lead to the risk of having seizures as well as how they generate, propagate and terminate (Wendling, 2005). Mathematical models that combine experimental and clinical detail at diverse scales have revealed the importance of many microscopic and macroscopic mechanisms in the generation of seizure-like activity, ranging from genetic and molecular mechanisms to changes in the excitability of neural populations leading to the generation of pathological oscillations (for review see Woldman & Terry (2015); Soltesz & Staley (2008)). Due to the increased availability of data recordings (EEG, MRI, MEG, CT, PET), there has been a significant increase in research studies that aim to identify novel biomarkers from these recordings with potential clinical value, using various different techniques (e.g. time-series analysis, computational modelling, machine learning). By combining mathematical and computational techniques, we have identified properties in the resting-state EEG (eyes closed, relaxed) of people with epilepsy that differ from those of controls as well as their first-degree relatives (Chowdhury et al., 2014). Developing these approaches and applying them to routine recordings from individuals with epilepsy against a control cohort (Schmidt et al., 2016) revealed levels of diagnostic accuracy similar to current general (i.e. non-specialist) neurology practices (60% sensitivity, 87% specificity, N=68). Crucially, our method correctly classified several subjects using their first EEG, whereas clinical diagnosis was confirmed only after prolonged telemetric recordings over many months. Since our methods and analysis depend on short segments of resting-state EEG only, its accuracy and efficacy do not rely on capturing epileptiform abnormalities, in contrast to the current use of EEG in diagnosing epilepsy. Since many EEGs return negative, clinicians are often faced with the problem of deciding on whether to opt for longer recordings of EEG or ambulatory or video EEG, which is currently the final method in the diagnostic cascade. This is time-consuming, expensive and relies on the availability and expertise of trained EEG-readers. By optimally interrogating short segments of background activity with mathematical and computational analysis, our methods, in the short term, provide additional evidence that could guide clinicians in future diagnostic steps.


Recruitment information / eligibility

Status Completed
Enrollment 825
Est. completion date March 31, 2022
Est. primary completion date December 31, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Subject was suspected of having had a seizure or epilepsy (fits, faints or funny turns), and as part of the diagnostic process one or more EEGs was recorded The subject ended up with a confirmed diagnosis of epilepsy or of the differential diagnosis such as syncope, or psychogenic seizures (diagnosis must have been at least 1 year ago, and not changed since) For each subject identified we would like to have all the available EEG files within the centre, with the following metadata: Primary meta-data (crucial): Age at the subject at time of each available EEG Treatment status at the time of each available EEG (including drug-load) Gender of the individual Ethnicity of the individual Confirmed diagnosis: details on the exact diagnosis made (syndrome and or condition) Secondary meta-data (optional): Aim of each available EEG at the time Information on whether any other conditions are present such as Alzheimer's disease, schizophrenia, Intellectual Disability If available: information on when the diagnosis was made If available: interpretation of each available EEG Specifics for the EEG recordings: Montage (10-20 preferred) Number of channels (minimum 19 channels) Referencing method (common average preferred) Format of the file (EDF preferred) Consistent channel labels for all EEGs provided from each centre Information concerning the time of day during the recording Information on the sampling frequency Faulty channels (not more than 2 preferred, all should be indicated though) Pre-processing details (information as to whether any filters were used, for example) Exclusion Criteria: Subject was not suspected of having had a seizure or epilepsy Unavailable information concerning the final diagnosis of the subject (epilepsy or other) Incomplete or unreliable meta-data, such as the age, gender and treatment-status at the time of the EEG recording (primary meta-data) Recordings which do not comply with inclusion criteria

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United Kingdom Cornwall Partnership NHS Foundation Trust Bodmin Cornwall

Sponsors (2)

Lead Sponsor Collaborator
Cornwall Partnership NHS Foundation Trust Neuronostics Ltd

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary To validate a set of computational biomarkers as potential decision support in epilepsy on a large cohort of study participants that were diagnosed with epilepsy and controls that ended up with another diagnosis To each EEG recording, we apply an algorithm that automatically detects relevant segments to our analysis (free of artefacts). By combining the individually derived network structure with the mathematical model, we simulate a computer-generated EEG, which serves as a proxy for the original segment derived from the study participant. We then examine this computer-generated EEG by calculating two biomarkers:
A global marker that quantifies how easy it is for the entire network to make the transition to seizure activity in the model
A local marker that quantifies whether there are particular regions in the network that are particular prone to generating or participating in seizure activity in the model.
31/12/2022
Secondary To examine whether the computational biomarkers could contribute to reducing the waiting time and the number of clinical appointments needed before a final diagnosis is made. To each EEG recording, we apply an algorithm that automatically detects relevant segments to our analysis (free of artefacts). By combining the individually derived network structure with the mathematical model, we simulate a computer-generated EEG, which serves as a proxy for the original segment derived from the study participant. We then examine this computer-generated EEG by calculating two biomarkers:
A global marker that quantifies how easy it is for the entire network to make the transition to seizure activity in the model
A local marker that quantifies whether there are particular regions in the network that are particular prone to generating or participating in seizure activity in the model.
31/12/2022
See also
  Status Clinical Trial Phase
Completed NCT04595513 - Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants Phase 1/Phase 2
Completed NCT02909387 - Adapting Project UPLIFT for Blacks in Georgia N/A
Completed NCT05552924 - Self Acupressure on Fatigue and Sleep Quality in Epilepsy Patients N/A
Terminated NCT01668654 - Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS Phase 3
Not yet recruiting NCT05068323 - Impact of Interictal Epileptiform Activity on Some Cognitive Domains in Newly Diagnosed Epileptic Patients N/A
Completed NCT03994718 - Creative Arts II Study N/A
Recruiting NCT04076449 - Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy
Completed NCT00782249 - Trial Comparing Different Stimulation Paradigms in Patients Treated With Vagus Nerve Stimulation for Refractory Epilepsy N/A
Completed NCT03683381 - App-based Intervention for Treating Insomnia Among Patients With Epilepsy N/A
Recruiting NCT05101161 - Neurofeedback Using Implanted Deep Brain Stimulation Electrodes N/A
Active, not recruiting NCT06034353 - Impact of Pharmacist-led Cognitive Behavioral Intervention on Adherence and Quality of Life of Epileptic Patients N/A
Recruiting NCT05769933 - Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
Not yet recruiting NCT06408428 - Glioma Intraoperative MicroElectroCorticoGraphy N/A
Not yet recruiting NCT05559060 - Comorbidities of Epilepsy(Cognitive and Psychiatric Dysfunction)
Completed NCT02977208 - Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use Phase 4
Completed NCT02952456 - Phenomenological Approach of Epilepsy in Patients With Epilepsy
Completed NCT02646631 - Behavioral and Educational Tools to Improve Epilepsy Care N/A
Recruiting NCT02539134 - TAK-935 Multiple Rising Dose Study in Healthy Participants Phase 1
Terminated NCT02757547 - Transcranial Magnetic Stimulation for Epilepsy N/A
Completed NCT02491073 - Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL) N/A